![\"ulcerative](\"https:\/\/venturaclinicaltrials.com\/wp-content\/uploads\/2016\/06\/clinical-trials-recruiting-300x150.jpg\")
<\/p>\nLike many ULCERATIVE COLITIS (UC) patients, your doctor has prescribed mesalamine to treat your UC. While mesalamine can be effective against UC for some patients, other UC patients continue to struggle with symptoms of their disease
\nTo pre-qualify for this study, you must be:<\/p>\n
As a result, you may be considering additional options for
\nlong-term treatment of your UC.
\nOne option is this research study of an investigational drug that is taken along with your mesalamine prescription. In this study, local doctors want to evaluate an investigational drug called
\nLT-02 as an add-on treatment for UC.
\nThe investigational drug, which is soy-based, is a delayed-release drug that is in the form of pellets and taken twice a day before a meal.
\nDoctors want to compare LT-02 with placebo, which looks like the investigational drug, but contains no active medication. The results of this study will provide more information about the investigational drug and whether it could one day be used as an add-on treatment with current UC medications.<\/p>\n
Who is eligible to participate in this study?<\/p>\n
<\/p>\n
All study-related visits, tests, and drugs will be provided to participants at no cost. In addition, compensation for study-related time and travel may be provided.
\nIf you do not meet these eligibility criteria right now, but do so at a future date, please contact the study coordinator about your eligibility, using the telephone number on the back of this brochure.<\/p>\n
Before you can participate in the study, you must first be screened for eligibility. If you are eligible, and you agree to participate, you will be randomly assigned to one of two study groups. You, the study doctor, and the study staff will not know which study drug (investigational or placebo) you are receiving. This is to prevent any opinions about the study drugs from affecting the results of the study. However, in the event of an emergency, this information will be provided. You total study participation will last approximately 20 weeks and includes 6 study clinic visits for treatment and You will also be given an electronic diary and asked to record your daily UC symptoms and study drug dosing details. This diary must be completed every day in order for you to remain in the study. As with any medical research study, your study drug may not help your UC. The investigational medication has been studied before and most patients in those studies tolerated it well. However, it is possible that you could experience a side effect while in this study.<\/p>\n You will be closely monitored throughout this study. Researchers for this study are required to follow the study protocol, which explains all study procedures in detail. An independent review board responsible for patient safety has reviewed these procedures and approved this protocol.<\/p>\n What if I have questions?<\/p>\n Save<\/span><\/p>\n Save<\/span><\/p>\n Save<\/span><\/p>\n Save<\/span><\/p>\n Save<\/span><\/p>\n Save<\/span><\/p>\n Save<\/span><\/p>\n Save<\/span><\/p>\n","protected":false},"excerpt":{"rendered":" Like many ULCERATIVE COLITIS (UC) patients, your doctor has prescribed mesalamine to treat your UC. While mesalamine can be effective against UC for some patients, other UC patients continue to struggle with symptoms of their disease To pre-qualify for this study, you must be: As a result, you may be considering additional options for long-term […]<\/p>\n","protected":false},"author":1,"featured_media":274,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,47,48],"tags":[57,58,56,55,13,40,41,53,51,50,49,52,54],"class_list":["post-273","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-trials","category-ulcerative-colitis-clinical-trials","category-ulcerative-colitis-clinical-trials-in-ventura","tag-la","tag-los-angeles","tag-malibu","tag-oxnard","tag-ulcerative-colitis","tag-ulcerative-colitis-clinical-trials","tag-ulcerative-colitis-clinical-trials-in-ventura","tag-ulcerative-colitis-clinical-research","tag-ulcerative-colitis-clinical-trials-la","tag-ulcerative-colitis-clinical-trials-malibu","tag-ulcerative-colitis-clinical-trials-oxnard","tag-ulcerative-colitis-trials","tag-ventura","post-preview"],"_links":{"self":[{"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=\/wp\/v2\/posts\/273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=273"}],"version-history":[{"count":14,"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=\/wp\/v2\/posts\/273\/revisions"}],"predecessor-version":[{"id":554,"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=\/wp\/v2\/posts\/273\/revisions\/554"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=\/wp\/v2\/media\/274"}],"wp:attachment":[{"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/venturaclinicaltrials.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nOne group will receive the investigational drug<\/a> and one group will receive placebo<\/a>. You have a 67% (2\/3) chance of receiving the investigational drug and a 33% (1\/3) chance of receiving placebo.<\/p>\n
\nNo matter which study drug you receive, you will take it in the morning and evening 30 to 60 minutes before a meal. You may mix your study drug with water, juice, milk, or yogurt. You will take your study drug twice a day for 12 weeks.<\/p>\n
\nfollow-up. Additionally, you will receive 1 phone call from the study staff. During your study clinic visits, study doctors and staff members will evaluate your health and progress through various tests and assessments. Some of these include, but are not limited to:<\/p>\n\u2022 Physical exams<\/a>
\n\u2022 Vital signs measurements
\n\u2022 Blood and urine sample collections
\n\u2022 Endoscopy<\/a> (looks at the lining of your colon<\/a>)
\n\u2022 UC assessments
\n\u2022 Quality of life and work productivity questionnaires
\n\u2022 Reviews of medications you are currently taking<\/h6>\n
\nIf you complete the study, you may have the option to participate in an extension study in which all patients will receive the investigational drug.<\/p>\nWhat are the risks and benefits related to this study?<\/h5>\n
The study staff is always available to answer any questions or concerns you may have about the study or the study drugs<\/h6>\n
To find out if you qualify for this study and compensation\u00a0 please fill out form and call 1800 920 0016<\/h3>\n